Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
0.1689
+0.0169 (11.12%)
Jun 18, 2026, 4:00 PM EDT - Market closed
Calidi Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
29
Market Cap
2.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 45.00K | -404.00K | -89.98% |
| Dec 31, 2021 | 449.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ensysce Biosciences | 4.71M |
| GeoVax Labs | 852.28K |
| VivoSim Labs | 142.00K |
| Biodexa Pharmaceuticals | 104.90K |
| Azitra | 7.50K |
| Virax Biolabs Group | 2.99K |
CLDI News
- 3 days ago - Calidi receives pre-IND regulatory feedback from FDA for CLD-401 - TheFly
- 3 days ago - Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study - GlobeNewsWire
- 11 days ago - Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026 - GlobeNewsWire
- 24 days ago - Calidi announces online abstract acceptances at 2026 ASCO Meeting - TheFly
- 24 days ago - Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting - GlobeNewsWire
- 4 weeks ago - Calidi provides required NYSE American disclosure - TheFly
- 4 weeks ago - Calidi Biotherapeutics Provides Required NYSE American Disclosure - GlobeNewsWire
- 5 weeks ago - Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights - GlobeNewsWire